» Articles » PMID: 20965876

Urinary 8-hydroxy-2'-deoxyguanosine Reflects Symptomatic Status and Severity of Systolic Dysfunction in Patients with Chronic Heart Failure

Overview
Publisher Wiley
Date 2010 Oct 23
PMID 20965876
Citations 22
Authors
Affiliations
Soon will be listed here.
Abstract

Aims: Oxidative stress is known to play a crucial role in the pathogenesis of heart failure (HF). We investigated whether urinary 8-hydroxy-2'-deoxyguanosine (8-OHdG), a product of oxidative DNA damage, is a clinically useful biomarker of the severity of chronic heart failure (CHF) and oxidative stress levels in failing hearts.

Methods And Results: We measured 8-OHdG in the serum obtained from the coronary sinus (CS) and aortic root (Ao) in small groups of control subjects and CHF patients. We then measured urinary 8-OHdG and other biomarkers (brain natriuretic peptide, 8-isoplastane, high-sensitivity C-reactive protein, interleukin-6, and tumour necrosis factor-α) in 31 control subjects and 194 patients with CHF [left-ventricular ejection fraction (LVEF): 28.3 ± 8.1%]. Serum 8-OHdG was significantly higher in the CS than the Ao in CHF patients only. Urinary 8-OHdG was also significantly higher in CHF patients than in control subjects, and urinary 8-OHdG became higher as New York Heart Association class increased. Moreover, there was a significant correlation between urinary 8-OHdG and LVEF (r = -0.27), pulmonary capillary wedge pressure (r = 0.31), or left-ventricular end-diastolic volume index (r = 0.22). In contrast, there was poor correlation between the severity of CHF and the other neurohumoral biomarkers.

Conclusion: In HF, urinary 8-OHdG seems to reflect the level of oxidative stress and various parameters related to symptomatic status and functional severity of CHF.

Citing Articles

Tofogliflozin reduces sleep apnea severity in patients with type 2 diabetes mellitus and heart failure: a prospective study.

Ishiwata S, Kasai T, Sato A, Suda S, Matsumoto H, Shitara J Hypertens Res. 2024; 48(1):388-397.

PMID: 39528646 DOI: 10.1038/s41440-024-01982-3.


Emerging Biomarkers in Cardiac Sarcoidosis and Other Inflammatory Cardiomyopathies.

Roumi J, Taimeh Z Curr Heart Fail Rep. 2024; 21(6):570-579.

PMID: 39365404 PMC: 11511729. DOI: 10.1007/s11897-024-00683-9.


Cardiovascular adaptations and pathological changes induced by spaceflight: from cellular mechanisms to organ-level impacts.

Han H, Jia H, Wang Y, Song J Mil Med Res. 2024; 11(1):68.

PMID: 39334239 PMC: 11429428. DOI: 10.1186/s40779-024-00570-3.


Efficacy and safety of the urate-lowering agent febuxostat in chronic heart failure patients with hyperuricemia: results from the LEAF-CHF study.

Yokota T, Kinugawa S, Fukushima A, Okumura T, Murohara T, Tsutsui H Heart Vessels. 2024; 40(2):111-122.

PMID: 39158751 DOI: 10.1007/s00380-024-02448-9.


Novel Oxidative Stress Biomarkers with Risk Prognosis Values in Heart Failure.

Ng M, Ang X, Yap K, Ng J, Goh E, Khoo B Biomedicines. 2023; 11(3).

PMID: 36979896 PMC: 10046491. DOI: 10.3390/biomedicines11030917.